tradingkey.logo

Successful Readout Of Prospective Phase 2 Sinergy Trial Supports Signateratm Mrd-Guided Treatment

ReutersFeb 24, 2026 11:07 AM

- Natera Inc NTRA.O:

  • SUCCESSFUL READOUT OF PROSPECTIVE PHASE 2 SINERGY TRIAL SUPPORTS SIGNATERATM MRD-GUIDED TREATMENT IN HEAD AND NECK CANCER

  • NATERA INC - TRIAL ACHIEVES 63% RESPONSE RATE, REDUCES CHEMOTHERAPY IN 74% OF PATIENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI